RemSleep Holdings Inc.: Form 10-Q for the period ended Sep 30, 2025
Filed with the SEC on Nov 19, 2025 and accepted by EDGAR at Nov 19, 2025, 16:17 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2025-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2025-07-01 to 2025-09-30 | $7.5k | us-gaap:Revenues |
| Revenue | 9 months2025-01-01 to 2025-09-30 | $12.3k | us-gaap:Revenues |
| Cost of revenue | 3 months2025-07-01 to 2025-09-30 | $28 | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2025-01-01 to 2025-09-30 | $628 | us-gaap:CostOfRevenue |
| Gross profit | 3 months2025-07-01 to 2025-09-30 | $7.4k | us-gaap:GrossProfit |
| Gross profit | 9 months2025-01-01 to 2025-09-30 | $11.7k | us-gaap:GrossProfit |
| Research and development | 9 months2025-01-01 to 2025-09-30 | $18.7k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2025-07-01 to 2025-09-30 | −$2.3m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-01-01 to 2025-09-30 | −$2.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2025-07-01 to 2025-09-30 | $130.1k | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2025-01-01 to 2025-09-30 | $350.1k | us-gaap:InterestExpenseNonoperating |
| Net income | 3 months2025-07-01 to 2025-09-30 | −$2.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-01-01 to 2025-09-30 | −$2.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2025-07-01 to 2025-09-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2025-01-01 to 2025-09-30 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2025-07-01 to 2025-09-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2025-01-01 to 2025-09-30 | $0.00 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2025-07-01 to 2025-09-30 | 1,577,123,665 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2025-01-01 to 2025-09-30 | 1,549,248,223 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-01-01 to 2025-09-30 | −$373.4k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2025-09-30 | $343.9k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2025-09-30 | $372.7k | us-gaap:AssetsCurrent |
| Total assets | At period end2025-09-30 | $464.1k | us-gaap:Assets |
| Current liabilities | At period end2025-09-30 | $202.5k | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2025-09-30 | $214.7k | us-gaap:Liabilities |
| Shareholders' equity | At period end2025-09-30 | $249.3k | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-25-112640. Last ingested by Listed: Oct 24, 2026, 15:09 ET. Listed shows no prices and gives no investment advice.